Преждевременная менопауза у больных системной красной волчанкой: факторы риска, роль терапии цитостатиками


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Представлены факторы риска и патогенез преждевременной менопаузы у больных системной красной волчанкой. Специально обсуждена роль гонадотосичности цитостатиков, в частности циклофосфамида.

Полный текст

Доступ закрыт

Об авторах

С. Ю Серикова

ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова», Минздрава России

Email: kariatida1@yandex.ru
к.м.н. Москва

Н. Л Козловская

ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова», Минздрава России

профессор кафедры нефрологии и гемодиализа д.м.н. Москва

И. Н Бобкова

ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова», Минздрава России

заведующая отделом нефрологии НИИ уронефрологии д.м.н. Москва

Список литературы

  1. Blumenfeld Z., Halachmi Sar’el, Alik Peretz B. et al. Premature ovarian failure — the prognostic application of autoimmunity on conception after ovulation induction // Fertil Steril. — 1993; 59:76-81.
  2. Shuster L.T., Rhodes D.J., Gostout B.S. et al. Premature menopause or early menopause: long-term health consequences//Maturitas. — 2010; 65(2): 161.
  3. Carp H.J.A., Selmi C., Shoenfeld Y. The autoimmune bases of infertility and pregnancy loss// Journal of Autoimmunity. — 2012; 38: J266—J274.
  4. Baba S., Katsumata Y, Kawaguchi Y. et al. Association between low-dose pulsed intravenous cyclophosphamide therapy and amenorrhea in patients with systemic lupus erythematosus: A case-control study // BMC Women's Health. — 2011; 11:28. doi: 10.1186/1472-6874-11-28.
  5. Medeiros M.M.C., Silveira V.A.L., Menezes A.P.T. et al. Risk factors for ovarian failure in patients with systemic lupus erythematosus // Braz J Med Biol Res. — 2001; 34(12):1561—1568.
  6. Fatnoon N.N.A., Azarisman S.M.S., Zainal D. Prevalence and risk factors for menstrual disorders among systemic lupus erythematosus patients // Singapore Med J. — 2008; 49 (5): 413.
  7. Gonzalez L.A., McGwin G.Jr., Duran S. et al. Predictors of premature gonadal failure in patients with systemic lupus erythematosus. Results from LUMINA, a multiethnic US cohort (LUMINA LVIII) for the LUMINA Study Group // Ann Rheum Dis. — 2008; 67:1170—1173.
  8. Ioannidis J.P.A., Katsifis G.E., Tzioufas A.G. et al. Predictors of Sustained Amenorrhea from Pulsed Intravenous Cyclophosphamide in Premenopausal Women with Systemic Lupus Erythematosus // J Rheumatol. — 2002; 29:2129—2135.
  9. Biscotti C.V., Hart W.R. and Lucas J.G. Cystic enlargement resulting from autoimmune oophoritis //Obstet Gynecol. — 1989; 74:492—495.
  10. Kalantaridou S.N., Braddock D.T., Patronas N.J. et al. Treatment of autoimmune premature ovarianfailure: Case report//Hum. Reprod. — 1999; 14(7):1777—1782.
  11. Cowchock F.S., McCabe J.L., Montgomery B.B. Pregnancy after corticosteroid administration in premature ovarian failure (polyglandular endocrinopathy syndrome) // Am J Obstet Gynecol. — 1988; 158(1):118—119.
  12. Kasteren Y.M. van, Braat D.D.M., Hemrika D.J. et al. Corticosteroids do not influence ovarian responsiveness to gonadotropins in patients with premature ovarian failure: a randomized, placebo-controlled trial // Fertil Steril. — 1999; 71(1): 90—95.
  13. Chiauzzi V., Cigorraga S., Escobar M.E. et al. Inhibition of follicle-stimulating hormone receptor binding by circulating immunoglobulins // J Clin Endocrinol Metab. — 1982; 54:1221—1228.
  14. Moncayo H., Moncayo R., Benz R. et al. Ovarian failure and autoimmunity. Detection of autoantibodies directed against both the unoccupied luteinizing hormone/human chorionic gonadotropin receptor and the hormone-receptor complex of bovine corpus luteum // J Clin Invest. — 1989; 84:1857—1865.
  15. Pasoto S.G., Viana V.S., Mendonca B.B. et al. Anticorpus luteum antibody: a novel serological marker for ovarian dysfunction in systemic lupus erythematosus?// J Rheumatol. — 1999; 26:1087-1093.
  16. Tang V.W., Faiman C. Premature ovarian failure: a search for circulating factors against gonadotropin receptors// Am J Obstet Gynecol. — 1983; 146:816-821.
  17. Novosad J.A., Kalantaridou S.N., Tong Z.B. et al. Ovarian antibodies as detected by indirect immunofluorescence are unreliable in the diagnosis of autoimmune premature ovarian failure: a controlled evaluation // BMC Womens Health. — 2003; 3:2.
  18. Cabral de Sousa C.D., das Chagas Medeiros M.M., Trindade Viana V.S. et al. Anticorpus luteum antibody and menstrual irregularity in patients with systemic lupus erythematosus and Hashimoto's thyroiditis//Lupus. — 2005;14(8):618—624.
  19. Lim G.S., Petri M., Goldman D. Menstruation and systemic lupus erythematosus: a case-control study // Arthritis and Rheumatism. — 1993; 36(Suppl 5): R23.
  20. Appenzeller S., Blatyta P.F., Costallat L.T. Ovarian failure in SLE patients using pulse cyclophosphamide: comparison of different regimes// Rheumatol Int. — 2008; 28(6):567—571.
  21. Mok C.C., Lau C.S., Wong R.W. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. // Arthritis Rheum. —1998; 41(5):831—837.
  22. Shabanova S.S., Ananieva L.P., Alekberova Z.S. et al. Ovarian function and disease activity in patients with systemic lupus erythematosus // Clin Exp Rheumatol. — 2008; 26(3):436—441.
  23. Gomez F., de la Cueva R., Wauters J.P. et al. Endocrine abnormalities in patients undergoing long-term hemodialysis. The role of prolactin // Am J Med. — 1980; 68:522—530.
  24. Contreras G., Tozman E., Nahar N. et al. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide // Lupus. — 2005; 14 Suppl 1: 33—38.
  25. Velàsquez Méndez M.P., Ramirez Ruiz F.A., Vàsquez Duque G.M. et al. Prevalence of ovarian failure and risk factor in patients with systemic lupus erythematosus // Rev.Colomb.Reumatol. — 2006; 13(3):189—197.
  26. Насонова В.А., Иванова М.М., Самойлова С. Т. Материалы отчетной сессии Ин-та ревматизма АМН СССР за 1969 и 1970 гг. — М., 1971. 61.
  27. Ataya K.M., Valeriote F.A., Raniuhi-Ataya A.J. Effect of Cyclophosphamide on the Immature Rat Ovary// Cancer Research. — 1989; 49 (1): 1660—1664.
  28. Meirow D., Lewis H., Nugent D. et al. Sublinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool // Hum Reprod. — 1999; 14: 1903—1907.
  29. Manger K., Wildt L., Kalden J.R. et al. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study // Autoimmun Rev. — 2006; 5:269—272.
  30. Laskari K., Zintzaras E., Tzioufas A.G. Ovarianfunction is preserved in women with severe systemic lupus erythematosus after a 6-month course of cyclophosphamide followed by mycophenolate mofetil// Clin Exp Rheumatol. — 2010; 28(1):83—86.
  31. Houssiau F.A., Vasconcelos C., D'Cruz D. et al. Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial oflow-dose versus highdose intravenous cyclophosphamide//Arthritis Rheum. — 2002; 46:2121—2131.
  32. Illei G.G., Austin H.A., Crane M. et al. Combination Therapy with Pulse Cyclophosphamide plus Pulse Methylprednisolone Improves Long-Term Renal Outcome without Adding Toxicity in Patients with Lupus Nephritis // Ann Intern Med. — 2001; 135:248—257.
  33. Frutos M.A., Martin Gómez A., de Ramón E. et al. Intravenous cyclophosphamide in lupus nephritis: twenty years reducing dose // Nefrologia. — 2007; 27(1):12—22.
  34. Henderson L., Masson P., Craig J.C. et al. Treatment for lupus nephritis (Review). The Cochrane Library. — 2012, Issue 12.
  35. Bertsias G.K., Tektonidou M., Amoura Z. et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis // Ann Rheum Dis. — 2012; 71(11):1771—1782.
  36. Langevitz P., Klein L., Pras M. et al. The effect of cyclophosphamide pulses on fertility in patients with lupus nephritis // Am J Reprod Immunol. — 1992; 28: 157—158.
  37. Boumpas D.T., Austin H.A., Vaughan E.M. et al. Risk of sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy // Ann Intern Med. — 1993;119:366—369.
  38. McDermott E.M., Powell R.J. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide // Ann Rheum Dis. — 1996 Apr; 55(4):224—229.
  39. Серикова С.Ю., Козловская Н.Л., Шилов Е.М. Волчаночный нефрит как фактор риска атеросклероза у больных системной красной волчанкой// Тер. архив. — 2008; 6:52—58.
  40. Серикова С.Ю., Козловская Н.Л., Бобкова И.Н. Преждевременное развитие атеросклероза при системной красной волчанке: факторы риска // Клиническая нефрология. — 2013; 3:11—16.
  41. Bombardier C., Gladman D.D., Urowitz M.B. et al. Derivation of the SLEDAI: a disease activity index for lupus patients // Arthritis Rheum. — 1992; 35: 630—640.
  42. Wheeler C.A. Premature Ovarian Failure: treatment strategies // Journal of Reproduct. Immunol. — 1995; 76(5):130—131.
  43. Davis S.R. Premature Ovarian Failure//Мaturitas. — 1996; 23:1—18.
  44. Caulam C.B. Premature gonadal failure // Fertil Steril. — 1982; 38: 645—655.
  45. Ataya K., Pydyn E. Young J. et al. The uptake and metabolism of cyclophosphamide by the ovary // Sel Cancer Ther. — 1990; 6:83—692.
  46. Chapman R.M., Sutcliffe S.B. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin’s disease. // Blood. — 1981; 58:849—851.
  47. Longhi A., Pignotti E., Versari M. et al. Effect of oral contraceptive on ovarian function in young females undergoing neoadjuvant chemotherapy treatment for osteosarcoma // Oncol Rep. — 2003; 10:151—155.
  48. Dooley M.A., Nair R. Therapy Insight: preserving fertility in cyclophosphamide-treated patients with rheumatic disease // Nat Clin Pract Rheumatol. 2008; 4(5):250—257.
  49. Somers E.C., Marder W., Christman G.M. et al. Use of a gonadotropinreleasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus//Arthritis Rheum. — 2005; 52: 2761—2767.
  50. Friedman A.J., Harrison-Atlas D., Barbieri R.L. et al. A randomized, placebocontrolled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata // Fertil Steril. — 1989; 51: 251—256.
  51. Peng C., Fan N.C., Ligier M. et al. Expression and regulation of gonadotropin-releasing hormone (GnRH) and GnRH receptor messenger ribonucleic acids in human granulosa-luteal cells // Endocrinology. — 1994; 135:1740—1746.
  52. Castelo-Branco C., Nomdedeu. Use of gonadotropinreleasing hormone agonists in patients with Hodgkin’s disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy//Fertil Steril. — 2007; 87: 702—705.
  53. Blumenfeld Z., Avivi I., Ritter M. et al. Preservation offertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women // J Soc Gynecol Invest. — 1999; 6:229 —239.
  54. Pereyra Pacheco B., Mendez Ribas J.M., Milone G. et al. Use of GnRH analogsfor functional protection of the ovary and preservation offertility during cancer treatment in adolescents: a preliminary report // Gynecol Oncol. — 2001; 81:391—397.
  55. Blumenfeld Z., Eckman A. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a. J Natl Cancer Inst Monogr. — 2005; 34:40—43.
  56. Blumenfeld Z., Shapiro D., Shteinberg M. et al. Preservation offertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy // Lupus. — 2000; 9: 401—405.
  57. Danforth D.R., Arbogast L.K., Friedman C.I. Acute depletion of murine primordial follicle reserve by gonadotropin-releasing hormone antagonists//Fertil Steril. — 2005; 83:1333—1338.
  58. Meirow D., Assad G., Dor J. et al. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice // Hum Reprod. — 2004; 19:1294—1299.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах